Category Archives: Byetta Cancer

Featured Stories

1,000+ Australians Join DePuy ASR Hip Implant Class Action Lawsuit

A class action lawsuit filed in Australia over DePuy Orthopaedics’ recalled metal-on-metal ASR Hip Implants has signed up more than 1,000 plaintiffs. The attorneys representing the Australian ASR Hip Implant lawsuit plaintiffs recently told The Courier-Mail that damages in the lawsuit are expected to be worth more than $200 million. One ...

Read More

Metal-on-Metal Hip Replacement Concerns Grow in Canada

Canadian patients and doctors are voicing more concerns about metal-on-metal hip replacements, as health regulators around the world continue to investigate the safety of the devices. According to a report from the CBC, four companies have recently either recalled or suspended sales of metal-on-metal hip replacement devices, while a number ...

Read More

Dozens Receive Nonsterile Simulated Saline Solution

Dozens-Receive-Nonsterile-Simulated-Saline-Solution

The FDA said last week that more than 40 patients had received intravenous simulated saline that was not sterile and was not intended for human use.

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

Lawsuits over DePuy ASR Metal-on-Metal Hip Implants Continue to Mount

DePuy Orthopaedics and its parent, Johnson & Johnson, continue to be hit with lawsuits over recalled metal-on-metal DePuy ASR hip implants. Just yesterday, the national law firm of Parker Waichman LLP announced it had filed yet another DePuy ASR hip implant lawsuit, this time on behalf of a Virginia resident ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Two Men Found Dead of Carbon Monoxide Poisoning

Two Men Found Dead of Carbon Monoxide Poisoning at Long Island, New York Auto Shop

Two men were found dead of apparent carbon monoxide poisoning in a Holbrook, New York, auto-detailing shop Thursday night, Suffolk County police say.

Read More

New York City Council Calls for Zadroga Act to be Renewed

New York City Council Calls for Zadroga Act to be Renewed

New York City Council members are calling for the Zadroga Act, which provides compensation and medical treatment to 9/11 victims, to be renewed.

Read More

Oklahoma Woman Latest to Head to Court Over Alleged DePuy ASR Hip Implant Injuries

Lawsuits filed by alleged victims of DePuy Orthopaedics’ recalled ASR hip replacement devices continue to pile up in the multidistrict litigation currently underway in U.S. District Court, Northern District of Ohio. Most recently, a woman from Pryor, Oklahoma, filed suit alleging complications caused by a DePuy ASR hip implant ...

Read More

National Law Firms Calls for More FDA Action on Actos Bladder Cancer Threat

A national law firm is not satisfied with the way the U.S. Food & Drug Administration (FDA) has handled warnings regarding Actos (pioglitazone) bladder cancer risks. In a statement published today, Parker Waichman LLP called on the FDA to compel Takeda Pharmaceuticals, the maker of the type 2 diabetes drug, ...

Read More

Diabetes Drug-Pancreatitis Link Supported in Another Study

mimetic-diabtes-linked-to-pancreatitis

Another study has made a connection between Type 2 diabetes drugs known as incretin mimetics and increased rates of developing pancreatitis, a known precursor to pancreatic cancer. Incretin mimetics, are GLP-1-based diabetes therapies and include Byetta and Bydureon (exenatide); Victoza … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Former Pacific Grove Mayor’s Husband Sues Over Wife’s Pancreatic Cancer, Byetta Blamed

byetta_pancreatic_cancer_lawsuit

The husband of former Pacific Grove, Washington Mayor, Sandy Koffman just filed a wrongful death civil lawsuit against two drug companies following his wife’s death from pancreatic cancer last year. His wife had been taking Type 2 diabetes drug, Byetta. … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Gum Disease Tied to Increased Diabetes Risk, May Lead to Increased Risks Tied to Some Type 2 Diabetes Drugs

gum_disease_linked_to_diseases

The links between dental disease and other diseases have been growing, for instance dental disease has been tied to increased risks for developing diabetes and heart disease; pregnancy complications; and, potentially, dementia. Type 2 diabetes is typically treated with any … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

increting_drugs_side_effects

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Many Popular Medications Contain Cancer-Causing Compounds, May Increase Cancer Risks

medications_cancer_risks

Cancer is devastating, killing about 600,000 people every year. Cancer is, in fact, the second-leading cause of death in the United States. Yet, despite consumers’ proactive measures to avoid cancer-causing products, some pharmaceuticals might contain carcinogens, ameliorating the best consumer … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Type 2 Diabetes Medication Risks Examined in Journal Review

type2_diabetes_drugs

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Some Popular Diabetes Medications May Require Additional Review Over Potential Links to Pancreatic Cancer

Diabetes_Medications_Pancreatic_Cancer_Risk

Type 2 diabetes medications in the class known as incretin mimetics, such as Januvia and Byetta, are under increased scrutiny over recent studies discussing the drugs’ links to pancreatitis and potential increased risks to pancreatic cancer. The makers of these … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Januvia, Byetta, Other Diabetes Drugs Focus of Controversy

Januvia_Diabetes

Some popular and money making diabetes drugs are at the center of a conflict over disturbing research findings. Although Dr. Peter C. Butler declined to test its then-new diabetes medication, Januvia, he ultimately relented and, in 2008, observed that the … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Report: Diabetes Drugs Associated with Elevated Cancer Risks

A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer. Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are … Continue reading

Posted in Allentown Natural Gas Explosion, Byetta Cancer, Pharmaceuticals |

Following U.S. Study, European Union Investigating Diabetes Drugs

Following news in the United States about a recent study that found that Type 2 diabetes drugs, such as Januvia and Byetta, might place patients at increased risk for pancreatic damage, including pancreatic cell growth that could lead to cancer, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.